Mycoplasma Testing Market Size To Reach $2.81 Billion By 2033

November 2025 | Report Format: Electronic (PDF)

Mycoplasma Testing Market Growth & Trends

The global mycoplasma testing market size is expected to reach USD 2.81 billion by 2033, registering a CAGR of 11.94% from 2025 to 2033, according to a new report by Grand View Research, Inc. The major factors driving the expansion of market includes growing demand for mycoplasma testing in biomanufacturing, emerging economies, and growing pharmaceutical outsourcing. Additionally, the market's overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.

Growing number of government initiatives to support pharmaceutical and biotechnology companies is also driving the market growth. The U.S. FDA proposed to remove a test for detecting mycoplasma within in vitro living cell cultures, as it can help identify only a single test method. These changes in biologics regulations are anticipated to improve specificity and sensitivity in mycoplasma detection tests, leading to introduction of new technologies in the industry. This is expected to create immense opportunities for key players in new product development.

The rates of M. pneumoniae positivity sharply decreased during the COVID-19 pandemic outbreak at the end of 2019. This was a result of the COVID-19 pandemic's stringent regulations, which successfully stopped the spread of M. pneumonia. However, it is anticipated that M. pneumonia will expand even more throughout the research period following the relaxation of COVID-19 limits, which will have a positive impact on the mycoplasma testing market's growth.

Increasing investments in R&D have contributed significantly to the market’s revenue growth. With rising healthcare expenditure, research activities in the life sciences industry are increasing significantly. The adoption of new technologies for drug discovery & development and innovations in cell culture technologies are driving the demand for mycoplasma tests. The high risk of cell culture contamination remains the primary factor expected to drive the mycoplasma testing market over the forecast period

Mycoplasma is estimated to contaminate around 15%-35% of all continuous cell cultures around the world. Out of over 190 known species of mycoplasma, only eight species are responsible for more than 95% of cell culture contamination. Poor cultural practices, aerosols, dust, and cross-contamination as a result of faulty or broken laminar flow are some of the factors responsible for an increase in the number of cell culture contamination events. Such factors are likely to drive the market demand for mycoplasma testing solutions.

key Request a free sample copy or view report summary: Mycoplasma Testing Market Report

Mycoplasma Testing Market Report Highlights

Based on product, the kits and reagents segment dominated the global market and accounted for the largest revenue share of 55.72% in 2024. Services are expected to grow at the fastest CAGR over the forecast period.
Based on technology, the PCR segment held the largest revenue share of 47.14% in 2024. ELISA technology held the second largest market share during the forecast period.
Based on application, the cell line testing segment held the largest revenue share of 40.99% in 2024. End of production cells testing held the second-largest market share in 2024.
Based on end-use, the pharmaceutical and biotechnology companies segment received the highest revenue shares of 35.15% in 2024.
North America mycoplasma testing market dominated the global market and accounted for a revenue share of 40.52% in 2024.
The mycoplasma testing market in the Asia Pacific is estimated to grow at the fastest CAGR over the forecasted period.